Premium
Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin‐induced sensory neuropathy in gastrointestinal cancers
Author(s) -
Xu Xi Tao,
Dai Zhang Han,
Xu Qi,
Qiao Yu Qi,
Gu Yan,
Nie Fang,
Zhu Ming Ming,
Tong Jin Lu,
Ran Zhi Hua
Publication year - 2013
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12050
Subject(s) - oxaliplatin , medicine , odds ratio , gastroenterology , confidence interval , incidence (geometry) , sensory neuropathy , gastrointestinal cancer , calcium , cancer , colorectal cancer , physics , optics
Objective To derive a more precise estimation on the safety and efficacy of calcium and magnesium ( C a and M g) infusions in the prevention of oxaliplatin‐induced sensory neuropathy. Methods A total of 16 studies including 1765 individuals were involved in this meta‐analysis. Odds ratio ( OR ) and its 95% confidence interval ( CI ) were calculated. Results The difference in the incidence of oxaliplatin‐induced neuropathy grade ≥ 1 was statistically significant between the C a and M g infusions treatment group and the untreated group (National Cancer Institute common toxicity criteria [ NCI CTC ]: OR 0.44, 95% CI 0.31–0.62, P = 0.000; oxaliplatin‐specific scale [ OSS ]: OR 0.30, 95% CI 0.20–0.45, P = 0.000). Similar results were found in the incidences of oxaliplatin‐induced neuropathy grade ≥ 2 ( NCI CTC : OR 0.60, 95% CI 0.46–0.77, P = 0.000; OSS : OR 0.45, 95% CI 0.30–0.67, P = 0.000). However, we did not detect a trend of fewer oxaliplatin‐induced neuropathy grade ≥ 3 incidences in the Ca and Mg infusions treatment group than the untreated group ( NCI CTC : OR 0.67, 95% CI 0.44–1.01, P = 0.054; OSS : OR 0.66, 95% CI 0.34–1.29, P = 0.224). There was no difference in the response rate between the C a and M g treated group and the untreated group ( OR 0.89, 95% CI 0.67–1.17, P = 0.391). Conclusion C a and M g infusions do not alter the efficacy of oxaliplatin‐based chemotherapy in gastrointestinal cancers, which may be reasonable to add them to lessen the incidence of neuropathy.